share_log

Tonix Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer LEDERMAN SETH

Tonix Pharmaceuticals | 4/A:持股變動聲明(修正)-高管 LEDERMAN SETH

SEC announcement ·  03/06 17:06
Moomoo AI 已提取核心訊息
Seth Lederman, the Chief Executive Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), was reported to have engaged in a transaction involving the company's stock on February 27, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and total value of shares, were not disclosed in the announcement. As a result, the number of shares Lederman holds after the action remains unknown.
Seth Lederman, the Chief Executive Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), was reported to have engaged in a transaction involving the company's stock on February 27, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and total value of shares, were not disclosed in the announcement. As a result, the number of shares Lederman holds after the action remains unknown.
據報道,Tonix Pharmicals Holding Corp.(TNXP)首席執行官塞思·萊德曼於2024年2月27日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節,包括股票數量、股票性質、交易價格和股票總價值。因此,萊德曼在行動後持有的股票數量仍然未知。
據報道,Tonix Pharmicals Holding Corp.(TNXP)首席執行官塞思·萊德曼於2024年2月27日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節,包括股票數量、股票性質、交易價格和股票總價值。因此,萊德曼在行動後持有的股票數量仍然未知。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息